Announced details
Development of a treatment for interstitial cystitis/bladder pain syndrome (IC/BPS); urological diseases
The research and development project of あすか製薬 was selected for AMED's support program. あすか製薬 is a subsidiary of the company.
A national research and development agency that supports the research and development of pharmaceuticals and other products for intractable and rare diseases and promotes the practical application of innovative treatments originating in Japan. Other information, including its location, representative, capital and year of establishment, is Not disclosed.
No impact on consolidated results for the fiscal year ending March 2027
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | AKP-021 |
| Counterparty | Japan Agency for Medical Research and Development (AMED) |
| Counterparty overview | A national research and development agency that supports the research and development of pharmaceuticals and other products for intractable and rare diseases and promotes the practical application of innovative treatments originating in Japan. Other information, including its location, representative, capital and year of establishment, is Not disclosed. |
| Relationship with the Company | The research and development project of あすか製薬 was selected for AMED's support program. あすか製薬 is a subsidiary of the company. |
| Launch date | Preparing to initiate a Phase II clinical trial (start date: Not disclosed) |
| Applicable area | Development of a treatment for interstitial cystitis/bladder pain syndrome (IC/BPS); urological diseases |
| Impact on Business Performance | No impact on consolidated results for the fiscal year ending March 2027 |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The project supports the research and development of pharmaceuticals and other products for intractable and rare diseases and promotes the practical application of innovative treatments originating in Japan. The grant will support research and development toward initiating a Phase II clinical trial for AKP-021.